In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease
Molecules · 2023
DOI: 10.3390/molecules29010159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Man Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System…. Hauptthemen laut MEDLINE: Acute Kidney Injury, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province, Initial Scientific Research Fund of Yantai University, Graduate Innovation Foundation of Yantai University.
Abstract (Originalsprache)
Acute kidney injury (AKI) and chronic kidney disease (CKD) have become public health problems due to high morbidity and mortality. Currently, drugs recommended for patients with AKI or CKD are extremely limited, and candidates based on a new mechanism need to be explored. 84-B10 is a novel 3-phenylglutaric acid derivative that can activate the mitochondrial protease, Lon protease 1 (LONP1), and may protect against cisplatin-induced AKI and unilateral ureteral obstruction- or 5/6 nephrectomy [5/6Nx]-induced CKD model. Preclinical studies have shown that 84-B10 has a good therapeutic effect, low toxicity, and is a good prospect for further development. In the present study, the UHPLC-MS/MS method was first validated then applied to the pharmacokinetic study and tissue distribution of 84-B10 in rats. Physicochemical properties of 84-B10 were then acquired in silico. Based on these physicochemical and integral physiological parameters, a physiological based pharmacokinetic (PBPK) model was developed using the PK-Sim platform. The fitting accuracy was estimated with the obtained experimental data. Subsequently, the validated model was employed to predict the pharmacokinetic profiles in healthy and chronic kidney injury patients to evaluate potential clinical outcomes. Cmax in CKD patients was about 3250 ng/mL after a single dose of 84-B10 (0.41 mg/kg), and Cmax,ss was 1360 ng/mL after multiple doses. This study may serve in clinical dosage setting in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Ya…
- Nanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.
ORCID-Profile: Mengqiu Wu, Gangqiang Yang, Lin Wang
Förderung
- Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province
- Initial Scientific Research Fund of Yantai University
- Graduate Innovation Foundation of Yantai University
- Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province, Initial Scientific Research Fund of Yantai University
Zitieren
APA
Su, M., Liu, X., Zhao, Y., Zhu, Y., Wu, M., Liu, K., Yang, G., Liu, W., & Wang, L. (2023). In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease. Molecules. https://doi.org/10.3390/molecules29010159
Vancouver
Su M, Liu X, Zhao Y, Zhu Y, Wu M, Liu K, et al. In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease. Molecules. 2023. doi:10.3390/molecules29010159
BibTeX
@article{Su2023,
author = {Su, Man and Liu, Xianru and Zhao, Yuru and Zhu, Yatong and Wu, Mengqiu and Liu, Kun and Yang, Gangqiang and Liu, Wanhui and Wang, Lin},
title = {In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules29010159}
}
EUVIMED